425: ARCA Biopharma to Merge with Oruka Therapeutics, Securing $275M Investment

ARCA Biopharma is set to merge with Oruka Therapeutics in a reverse-triangle merger, accompanied by a $275 million private investment in Oruka.

Summary

• ARCA Biopharma and Oruka Therapeutics have announced a merger agreement.
• The transaction involves a reverse-triangle merger where ARCA will acquire 100% of Oruka's equity interests.
• Following the merger, ARCA will be renamed Oruka Therapeutics, Inc.
• Oruka has secured a $275 million private investment (PIPE) from healthcare investors.
• ARCA stockholders are expected to receive a dividend of approximately $20 million prior to the merger.
• Post-closing, Oruka holders are expected to own approximately 97.6% of the combined company, while ARCA holders will own about 2.4%.
• The total number of outstanding shares of the combined company is expected to be approximately 557.2 million.
• The closing of the transaction is anticipated to occur during the third quarter of 2024.
• Oruka's lead programs, ORKA-001 and ORKA-002, target the $50B+ global I&I market.
• ORKA-001 targets IL-23p19, while ORKA-002 targets IL-17A/F.

Sentiment

Score: 8

Explanation: The document presents a positive outlook for Oruka Therapeutics, highlighting its promising pipeline, significant funding, and potential for market leadership in the treatment of inflammatory skin diseases. The merger with ARCA Biopharma provides a pathway to becoming a publicly traded company, further enhancing its prospects.

Positives

• Oruka Therapeutics has secured significant funding of $275 million, providing runway through multiple clinical inflection points.
• The merger allows Oruka to become a publicly traded company.
• Oruka's programs target large and well-validated markets with significant growth potential.
• ORKA-001 has the potential to be a best-in-class IL-23p19 inhibitor with a longer half-life and less frequent dosing.
• ORKA-002 could be a best-in-class IL-17A/F inhibitor, addressing a $15B+ market.
• The development path for ORKA-001 is catalyst-rich, with potential for rapid de-risking and value recognition.
• Dermatologists view ORKA-001 as highly attractive, with potential for significant market share.
• ORKA-001 has the potential for disease modification or cure by depleting TRMs.

Negatives

• ARCA stockholders will have a small ownership stake (2.4%) in the combined company.
• The merger is subject to customary closing conditions, including regulatory approvals and stockholder approvals.
• The success of Oruka's programs depends on positive clinical trial results and regulatory approvals.
• The market for psoriasis and other inflammatory skin conditions is competitive.
• There is a risk of clinical trial delays or failures.
• There is a risk of competition from existing and new therapies.
• There is a risk of adverse events or safety concerns in clinical trials.

Risks

• The forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from expectations.
• The company's reliance on third-party data and forecasts may not be accurate or complete.
• The company's internal analyses and assumptions regarding the market and competitive position may not be accurate.
• The company's ability to obtain regulatory approvals for its products is uncertain.
• The company's ability to successfully commercialize its products is subject to market conditions and competition.
• The company's intellectual property rights may not be adequately protected.
• The company may face challenges in manufacturing and scaling up production of its products.
• The company may need to raise additional capital in the future.

Future Outlook

Oruka is focused on advancing its pipeline of monoclonal antibodies targeting inflammatory skin diseases, with multiple clinical milestones expected over the next three years.

Industry Context

The document highlights the competitive landscape of the psoriasis and inflammatory skin disease market, noting the potential for differentiated new entrants to gain share. It emphasizes the importance of IL-23p19 and IL-17A/F as established targets and the growing excitement around drugs with long dosing intervals.

Comparison to Industry Standards

• The document compares ORKA-001 to Skyrizi (risankizumab), highlighting its potential for a longer half-life and less frequent dosing.
• It also compares ORKA-002 to Bimzelx (bimekizumab), noting its potential to be a best-in-class IL-17A/F inhibitor.
• The document references the KNOCKOUT study, which evaluated higher doses of Skyrizi and resulted in higher PASI 100 rates.
• The document references the Bimzelx launch, validating both IL-17A/F and the ability to differentiate in PsO.

Stakeholder Impact

• Shareholders of ARCA Biopharma will have a small ownership stake in the combined company.
• Oruka Therapeutics will have access to public markets and increased visibility.
• Patients with inflammatory skin diseases may benefit from new and improved treatment options.
• Employees of both companies will be integrated into the new organization.

Next Steps

• Obtain regulatory approvals for the merger.
• Obtain stockholder approvals for the merger.
• Close the merger transaction.
• Advance ORKA-001 and ORKA-002 through clinical development.
• File Resale registration statement covering Oruka affiliates promptly post-closing.

Key Dates